CinnaGen is the first company from its region to receive a European marketing authorisation for a biosimilar. Present in more than 40 countries, CinnaGen is now coming to Europe for the first time.
On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Haleh Hamedifar, Chairperson of CinnaGen, about the approval and the partners CinnaGen is looking for in Europe.
In this episode, Haleh covers:
(00:27) Why the European marketing authorisation, the first for a biosimilar from CinnaGen's region, is so meaningful for the company.
(00:58) How an integrated model and in-house development let CinnaGen move faster and bring down costs, and why quality has to become part of a company's culture over years.
(02:43) The foundations a company needs to compete in a highly regulated market: an integrated system from R&D to market access, people who understand the science and the regulations, and shareholders with a long-term view.
(04:42) The partners CinnaGen is looking for at CPHI: reputable sales, marketing and market access partners in Europe, and co-development partners, for example on monoclonal antibodies.
Watch the full episode to hear how CinnaGen, with 20 years of experience producing complex biopharmaceuticals, is preparing for Europe.
Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent/
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Haleh Hamedifar
LinkedIn: https://www.linkedin.com/in/haleh-hamedifar-06516548/
Ruby Collier
LinkedIn: https://www.linkedin.com/in/ruby-collier/
Timestamps:
00:00 Introduction
00:43 Lessons from the European approval
02:24 Foundations for the European market
04:25 The partners CinnaGen wants at CPHI
05:48 Closing thoughts
#Newsbeat #ARTOTalent #CPHI #CPHIMilan #Biosimilars #Biopharma #MonoclonalAntibodies #MarketAccess
","author_name":"ARTO Talent"}